AcelRx Pharmaceuticals, Inc. (ACRX) saw its loss widen to $15.55 million, or $0.34 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $10.98 million, or $0.25 a share. Revenue during the quarter went up marginally by 2.78 percent to $3.11 million from $3.02 million in the previous year period. Gross margin for the quarter stood at negative 32.68 percent as compared to a negative 18.98 percent for the previous year period.
Operating loss for the quarter was $12.07 million, compared with an operating loss of $8.52 million in the previous year period.
"The first quarter of 2017 held two significant regulatory milestones: the acceptance of the DSUVIA NDA by the US FDA and the initiation of scientific review of the ARX-04 MAA by the European regulatory authority," stated Vincent J. Angotti, AcelRx's chief executive officer. "Over the next few months, the AcelRx team will be focused on our interactions with the FDA and EMA to support the potential approval and launch of DSUVIA in the US and ARX-04 in Europe."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]